LCB 18A
Alternative Names: LCB-18ALatest Information Update: 12 Jan 2022
At a glance
- Originator Unknown
- Developer LegoChem Biosciences
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 04 Jan 2022 LCB 18A is available for licensing as of 04 Jan 2022. https://www.legochembio.com/rnd/partners.php?lang=e
- 04 Jan 2022 Early research in Unspecified in South Korea (Parenteral), prior to January 2022 (LegoChem Biosciences pipeline, January 2022)